DEFAR - Departamento de Farmácia
URI permanente desta comunidadehttp://www.hml.repositorio.ufop.br/handle/123456789/530
Navegar
3 resultados
Resultados da Pesquisa
Item Miconazole-loaded nanoparticles coated with hyaluronic acid to treat vulvovaginal candidiasis.(2023) Teixeira, Aniely dos Reis; Quaresma, Amanda de Vasconcelos; Branquinho, Renata Tupinambá; Santos, Stephanie Lourrani Evangelista Neves; Magalhães, Juliana Teixeira; Silva, Fábio Henrique Rodrigues da; Marques, Maria Betânia de Freitas; Moura, Sandra Aparecida Lima de; Barboza, Ana Paula Moreira; Araújo, Marcelo Gonzaga de Freitas; Silva, Gisele Rodrigues daMiconazole-loaded nanoparticles coated with hyaluronic acid (miconazole-loaded nanoparticles/HA) were developed to overcome the limitations of the conventional therapy of the vulvovaginal candidiasis (VVC). They were synthesized by emulsification and solvent evaporation techniques, characterized by diameter, poly- dispersity index, zeta potential, encapsulation efficiency, atomic force microscopy (AFM), evaluated in terms of efficacy against C. albicans in vitro, and tested in a murine VVC model. Nanoparticles showed 211nm of diameter with a 0.32 polydispersity index, -53mV of zeta potential, and 90% miconazole encapsulation efficiency. AFM evidenced nanoparticles with a spherical shape. They inhibited the proliferation of C. albicans in vitro and in vivo after a single administration. Nanoparticles released the miconazole directly in the site of action at low thera- peutic doses, which was enough to eliminate the fungal burden in the murine VVC model. These systems were rationally designed since the existence of the HA induces their adhesion on the vaginal mucus and their inter- nalization via CD44 receptors, inhibiting the C. albicans. Therefore, miconazole-loaded nanoparticles/HA represent an innovative non-conventional pharmaceutical dosage form to treat the VVC and recurrent VVC.Item Spiramyin-loaded PLGA implants for the treatment of ocular toxoplasmosis : development, characterization, biocompatibility, and anti-toxoplasma activity.(2021) Tavares, Harley da Silva; Cardoso, Jéssica Ferreira; Almeida, Tamires Cunha; Marques, Maria Betânia de Freitas; Mussel, Wagner da Nova; Lopes, M. C. P.; Oréfice, Rodrigo Lambert; Andrade, Silmara Nunes; Varotti, Fernando de Pilla; Silva, Glenda Nicioli da; Silva, Gisele Rodrigues daOcular toxoplasmosis is the major cause of infectious posterior uveitis worldwide, inducing visual field defect and/or blindness. Despite the severity of this disease, an effective treatment is still lacking. In this study, spiramycin-loaded PLGA implants were developed aiming at the treatment of ocular toxoplasmosis. Implants were manufactured by a hot-molding technique, characterized by Fourier Transform Infrared Spectroscopy, X-Ray Diffraction, Differential Scanning Calorimetry, Scanning Electron Microscopy; evaluated in terms of ocular biocompatibility by immunofluorescence, flow cytometry, cell migration, Hen’s egg test-chorioallantoic membrane (HET-CAM) irritation test; and investigated in terms of in vitro efficacy against Toxoplasma gondii. Characterization techniques indicated that spiramycin was dispersed into the polymeric chains and both substances preserved their physical structures in implants. The HET-CAM test indicated that implants did not induce hemorrhage or coagulation, being non-irritant to the CAM. ARPE-19 cells showed viability by MTT assay, and normality in cell cycle kinetics and morphology, without stimulating cell death by apoptosis. Finally, they were highly effective against intracellular parasites without inducing human retinal pigment epithelial cell death. In conclusion, spiramycin-loaded PLGA implants represent a promising therapeutic alternative for the local treatment of ocular toxoplasmosis.Item Amphotericin B-loaded Eudragit RL100 nanoparticles coated with hyaluronic acid for the treatment of vulvovaginal candidiasis.(2020) Melo, Carolina Mirtes; Cardoso, Jéssica Ferreira; Perasoli, Fernanda Barçante; Oliveira Neto, Ari Soares de; Pinto, Luccas Moreira; Marques, Maria Betânia de Freitas; Mussel, Wagner da Nova; Magalhães, Juliana Teixeira de; Moura, Sandra Aparecida Lima de; Araújo, Marcelo Gonzaga de Freitas; Silva, Gisele Rodrigues daThe treatment of vulvovaginal candidiasis (VVC) is based on oral and vaginal formulations which show limited effectiveness. In this study, amphotericin B-loaded Eudragit RL100 nanoparticles coated with hyaluronic acid (AMP EUD nanoparticles/HA) were developed to overcome the drawbacks of the conventional formulations. AMP EUD nanoparticles/HA were synthesized by nanoprecipitation, formulated by statistical experimental design, and characterized. AMP release from EUD nanoparticles/HA and its antifungal activity in a murine model of VVC were evaluated. Nanoparticles showed 147.6 ± 16.7 nm of diameter, 0.301 ± 0.09 of polydispersity index, - 29.9 ± 3.76 mV of zeta potential, and 87.27 % of encapsulation efficiency. They released about 81 % of AMP in 96 h; and provided the elimination of 100 % of the vaginal fungal burden in 24 h. It was suggested that the AMP EUD nanoparticles/HA penetrated into the vaginal epithelium via CD44 receptors. These AMP EUD nanoparticles/HA represent a non-conventional vaginal formulation to improve the treatment of VVC.